Cargando…
S159: HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY
Autores principales: | Efficace, Fabio, Mahon, Francois-Xavier, Richter, Johan, Piciocchi, Alfonso, Cipriani, Marta, Nicolini, Franck Emmanuel, Hjorth-Hansen, Henrik, Almeida, Antonio, Janssen, Jeroen J. W. M., Mayer, Jiri, Koskenvesa, Perttu, Panayiotidis, Panayiotis, Olsson-Strömberg, Ulla, Martinez-Lopez, Joaquín, Rousselot, Philippe, Vestergaard, Hanne, Ehrencrona, Hans, Kairisto, Veli, Polakova, Katerina Machova, Mustjoki, Satu, Berger, Marc, Hochhaus, Andreas, Pfirrmann, Markus, Saussele, Susanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428462/ http://dx.doi.org/10.1097/01.HS9.0000967548.09724.54 |
Ejemplares similares
-
S155: PROGNOSTIC FACTORS FOR 3-YEAR MAJOR MOLECULAR RESPONSE MAINTENANCE IN CHRONIC MYELOID LEUKAEMIA PATIENTS IN THE EUROPEAN STOP KINASE INHIBITORS (EURO-SKI) TRIAL
por: Pfirrmann, Markus, et al.
Publicado: (2023) -
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI
por: Richter, Johan, et al.
Publicado: (2021) -
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
por: Hjorth-Hansen, Henrik, et al.
Publicado: (2015) -
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
por: Ilander, M, et al.
Publicado: (2017) -
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
por: Kreutzman, Anna, et al.
Publicado: (2019)